TG Therapeutics Inc. (NASDAQ:TGTX)’s share price shot up 14.8% on Wednesday . The stock traded as high as $7.22 and last traded at $7.14, with a volume of 832,087 shares changing hands. The stock had previously closed at $6.22.

Several research firms have recently weighed in on TGTX. Brean Capital restated a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, May 31st. FBR & Co restated a “buy” rating on shares of TG Therapeutics in a research report on Wednesday, May 4th. SunTrust Banks Inc. assumed coverage on TG Therapeutics in a research report on Friday, May 27th. They issued a “buy” rating and a $18.00 target price on the stock. Zacks Investment Research cut TG Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 14th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $33.00 price target on shares of TG Therapeutics in a report on Thursday, June 9th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. TG Therapeutics presently has an average rating of “Buy” and a consensus price target of $20.71.

The stock has a 50 day moving average of $5.99 and a 200-day moving average of $7.67. The firm’s market capitalization is $338.72 million.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. Equities analysts expect that TG Therapeutics Inc. will post ($1.23) EPS for the current year.

An institutional investor recently raised its position in TG Therapeutics stock. New York State Common Retirement Fund raised its stake in TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned about 0.43% of TG Therapeutics worth $2,671,000 as of its most recent filing with the SEC.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.